lenalidomide has been researched along with Anemia, Hemolytic, Autoimmune in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adamson, L; Eriksson, I; Gentilcore, G; Hansson, L; Heimersson, K; Mellstedt, H; Mozaffari, F; Mulder, TA; Näsman-Glaser, B; Österborg, A; Palma, M; Ryblom, H; Svensson, A | 1 |
| Barcellini, W; Cortelezzi, A; Fattizzo, B; Nesa, F; Sciumbata, VM; Zanella, A; Zaninoni, A | 1 |
| Álvarez Rivas, MÁ; Chic Acevedo, C; García Torres, E | 1 |
| Erdel, M; Fiegl, M; Kilga-Nogler, S; Köck, L; Schennach, H; Sun, WL; Walder, A | 1 |
| Akpek, G; Brauer, DL; Edelman, B; Hess, JR; Rapoport, AP | 1 |
| Darabi, K; Kantamnei, S; Wiernik, PH | 1 |
1 trial(s) available for lenalidomide and Anemia, Hemolytic, Autoimmune
| Article | Year |
|---|---|
Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Apoptosis; Cancer Vaccines; Combined Modality Therapy; Cyclophosphamide; Cytokines; Cytotoxicity, Immunologic; Dendritic Cells; Disease Progression; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Injections, Intravenous; Injections, Subcutaneous; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Thalidomide; Thrombocytopenia; Transplantation, Autologous; Tumor Cells, Cultured; Vaccination | 2018 |
5 other study(ies) available for lenalidomide and Anemia, Hemolytic, Autoimmune
| Article | Year |
|---|---|
Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Erythrocytes; Hemolysis; Humans; Immunologic Factors; Lenalidomide; Plasma Exchange; Rituximab; Severity of Illness Index; Splenectomy; Steroids; Thalidomide; Time-to-Treatment; Treatment Outcome | 2015 |
[Cold agglutinin disease of IgA class as early manifestation of multiple myeloma and resolution after treatment with new anti-myeloma drugs].
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin A; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide | 2016 |
Successful treatment of MDS with lenalidomide, complicated by transient autoimmune hemolysis.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Female; Humans; Immunoglobulins; Lenalidomide; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2010 |
Plasma exchange and rituximab treatment for lenalidomide-associated cold agglutinin disease.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Combined Modality Therapy; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Plasma Exchange; Rituximab; Thalidomide | 2012 |
Lenalidomide-induced warm autoimmune hemolytic anemia.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Female; Humans; Lenalidomide; Lymphoma, B-Cell; Thalidomide | 2006 |